Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Axovant Sciences
Biotech
As CEO goes, cash woes drive Sio to throw Parkinson's program
Years after the biotech, then known as Axovant, had a high-profile failure in Alzheimer’s, it has decided to cull its current riskiest gene therapy.
Nick Paul Taylor
Feb 1, 2022 7:05am
Roivant catches the SPAC wave to Wall Street in $611M deal
May 3, 2021 9:51am
David Hung, ex-Medivation execs join forces
Oct 28, 2019 8:50am
Axovant trumpets new clinical data after gene therapy pivot
Mar 11, 2019 10:38am
Enzyvant finds new CEO in former Alexion exec Rachelle Jacques
Feb 21, 2019 11:12am
Sanofi CMO takes on chief digital officer role—Chutes & Ladders
Feb 15, 2019 9:00am
